Nestlé SA emphasised in a statement on its website that the move is a financial investment, with no changes to the company’s operational control.
The new centre focuses on breeding tilapia with traits such as reddish-golden skin, strong disease resistance, and the ability to grow to at least 1kg—ideal for filleting and commercial sale.
The launch comes just a year after the company opened its fifth facility in Feira de Santana, Bahia, underscoring its aggressive growth strategy.
Lecithin, derived primarily from soybeans, serves as an effective emulsifier and stabiliser in compound feeds and is prized for its cost-efficiency and functionality in large-scale operations.
The distributed birds are suitable for both meat and egg production, and are expected to help address nutritional deficiencies and income instability in underserved areas.
The hub aims to produce 50 million fingerlings, 2,000 tonnes of ready-to-eat fish, 20,000 tonnes of processed fish, and 24,000 tonnes of fish feed annually.
Meanwhile, the European Commission recently approved Merck’s NOBILIS MULTRIVA™ REOm vaccine for chickens, designed to protect avian reovirus (ARV) genotypes 1 and 4.
By producing locally, European Protein expects to slash delivery times and freight costs, boosting its competitiveness in Southeast Asia.
The discussions focused on establishing a state-of-the-art facility in Egypt with a production capacity of up to 200 million vaccine doses annually.
USA – Kemin Industries, a global leader in ingredient manufacturing, has expanded its footprint in animal health innovation with the acquisition of Bactana®, a research-driven…